Vikram Purohit
Stock Analyst at Morgan Stanley
(0.82)
# 3,932
Out of 4,996 analysts
157
Total ratings
29.51%
Success rate
-12.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.73 | +115.75% | 3 | Aug 18, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $75 → $80 | $73.75 | +8.47% | 10 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.72 | +5.93% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $191.99 | +30.22% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $82.70 | -21.40% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $116.76 | +62.73% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $20.04 | +74.65% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.86 | +85.19% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $29.07 | +6.64% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $82.84 | -80.69% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.80 | +417.24% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $17.57 | -43.08% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.98 | +101.34% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.65 | +335.23% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $56.25 | -27.11% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $16.93 | +136.27% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.49 | +422.09% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.30 | +96.89% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.80 | +69.49% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.07 | -28.93% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.85 | +1,089.19% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.16 | +118.34% | 2 | Aug 5, 2020 |
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.73
Upside: +115.75%
Halozyme Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $75 → $80
Current: $73.75
Upside: +8.47%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.72
Upside: +5.93%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $191.99
Upside: +30.22%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $82.70
Upside: -21.40%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $116.76
Upside: +62.73%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $20.04
Upside: +74.65%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.86
Upside: +85.19%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $29.07
Upside: +6.64%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $82.84
Upside: -80.69%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $5.80
Upside: +417.24%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $17.57
Upside: -43.08%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.98
Upside: +101.34%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.65
Upside: +335.23%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $56.25
Upside: -27.11%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $16.93
Upside: +136.27%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.49
Upside: +422.09%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.30
Upside: +96.89%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.80
Upside: +69.49%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $14.07
Upside: -28.93%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.85
Upside: +1,089.19%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.16
Upside: +118.34%